Skip to main content
Premium Trial:

Request an Annual Quote

Cepheid Gets FDA OK for Thrombosis Test

NEW YORK (GenomeWeb News) – Cepheid said after the close of the market Thursday that the US Food and Drug Administration has cleared for marketing its Xpert HemosIL FII & FV test.

The test detects Factor II and V Leiden genetic variations associated with thrombophilia. It runs on the firm's GeneXpert system and provides results in just over 30 minutes. The test will be distributed exclusively by Instrumentation Laboratory.

The Xpert HemosIL FII & FV is Cepheid's eighth test to receive FDA clearance. IL launched the test in Europe in March 2008, and its CEO, Josep Manent, said in a statement that customer response there has been "extremely positive."

The Scan

US Booster Eligibility Decision

The US CDC director recommends that people at high risk of developing COVID-19 due to their jobs also be eligible for COVID-19 boosters, in addition to those 65 years old and older or with underlying medical conditions.

Arizona Bill Before Judge

The Arizona Daily Star reports that a judge weighing whether a new Arizona law restricting abortion due to genetic conditions is a ban or a restriction.

Additional Genes

Wales is rolling out new genetic testing service for cancer patients, according to BBC News.

Science Papers Examine State of Human Genomic Research, Single-Cell Protein Quantification

In Science this week: a number of editorials and policy reports discuss advances in human genomic research, and more.